Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)- ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6] -tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 467-475

  Xiao, Jim J ^a   Huang, Ying ^a   Dai, Zunyan ^a   Sadée, Wolfgang ^a   Chen, Jiyun ^a   Liu, Shujun ^a   Marcucci, Guido ^a   Byrd, John ^a   Covey, Joseph M ^b   Wright, John ^b   Grever, Michael ^a   Chan, Kenneth K ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FR 901228; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OLIGOMER;

ACETYLATION; ARTICLE; CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA MICROARRAY; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION; UPREGULATION; WESTERN BLOTTING;

ACETYLTRANSFERASES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN; DEPSIPEPTIDES; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; IMMUNOPRECIPITATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 23044440043     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083956     Document Type: Article

References (39)

1. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, and Scotto KW (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5:3352-3356.
2. Anderle P, Huang Y, and Sadee W (2004) Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. Eur J Pharm Sci 21:17-24.
3. Baker EK and El-Osta A (2003) The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 290:177-194.
4. Baylin SB, Herman JG, Graff JR, Vertino PM, and Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141-196.
5. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, et al. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105:959-967.
6. Cress WD and Seto E (2000) Histone deacetylases, transcriptional control and cancer. J Cell Physiol 184:1-16.
7. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, and Nelson WG (2004) MDR1 promoter hypermethylation in MCF-7 human breast cancer cell: changes in chromatin structure induced by treatment with 5-azacytidine. Cancer Biol Ther 3:540-548.
8. Davie JR and Chadee DN (1998) Regulation and regulatory parameters of histone modifications. J Cell Biochem Suppl 31:203-213.
9. El-Osta A, Kantharidis P, Zalcberg JR, and Wolffe AP (2002) Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 22:1844-1857.
10. El-Osta A and Wolffe AP (2001) Analysis of chromatin-immunopurified MeCP2-associated fragments. Biochem Biophys Res Commun 289:733-737.
11. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, et al. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4921.
12. Goodwin CJ, Holt SJ, Downes S, and Marshall NJ (1995) Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS. J Immunol Methods 179:95-103.
13. Grant PA and Berger SL (1999) Histone acetyltransferase complexes. Semin Cell Dev Biol 10:169-177.
14. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, and Sadee W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294-4301.
15. Jin S and Scotto KW (1998) Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18:4377-4384.
16. Kwon HJ, Kim MS, Kim MJ, Nakajima H, and Kim KW (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97:290-296.
17. Margueron R, Licznar A, Lazennec G, Vignon F, and Cavailles V (2003) Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 179:41-53.
18. Marks PA, Richon VM, and Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
19. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, et al. (2002) A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2:325-332.
20. Muller C, Laurent G, and Ling V (1995) P-Glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 163:538-544.
21. Nakajima H, Kim YB, Terano H, Yoshida M, and Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126-133.
22. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K, Kozuru M, Komatsu H, Ueda R, and Kuwano M (1998) Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92:4296-4307.
23. Naoe Y, Inoue T, Matsuo M, Mutoh S, and Kano Y (2004) The cytotoxic effects of FK228, histone deacetylase inhibitor, in combination with other anticancer agents. 95th American Association for Cancer Research Annual Meeting, 2004 March 27-31; Orlando, FL. Abstract #2449.
24. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728.
25. Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, and Sackett DL (2000a) FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11:445-454.
26. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, and Bates SE (2000b) P21-Dependent G(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83:817-825.
27. Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, Lee JS, Elgemeie GH, Stein WD, and Bates SE (1997) P-Glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 51:1024-1033.
28. Schinkel AH, Kemp S, Dolle M, Rudenko G, and Wagenaar E (1993) N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 268:7474-7481.
29. Schondorf T, Neumann R, Benz C, Becker M, Riffelmann M, Gohring UJ, Sartorius J, von Konig CH, Breidenbach M, Valter MM, et al. (2003) Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent Results Cancer Res 161:111-116.
30. Seelig A, Blatter XL, and Wohnsland F (2000) Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharmacol Ther 38:111-121.
31. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
32. Tan B, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
33. Vigushin DM and Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13.
34. Waterborg JH (2002) Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol 80:363-378.
35. Weidle UH and Grossmann A (2000) Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20:1471-1485.
36. Xiao J, Byrd J, Marcucci G, Grever M, and Chan KK (2003) Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom 17:757-766.
37. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadee W, Byrd J, Marcucci G, and Chan KK (2005) Efflux of depsipeptide FK228 (FR091228, NSC-630176) is mediated by both P-glycoprotein and MRP1. J Pharmacol Exp Ther 313:268-276.
38. Zhang Z, Wu JY, Hait WN, and Yang JM (2004) Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66:395-403.
39. Zhu WG, Lakshmanan RR, Beal MD, and Otterson GA (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61:1327-1333.